Treatment of Pure Red Cell Aplasia

Diagnostic Confirmation

• The National Kidney Foundation recommends confirming PRCA diagnosis in any patient who develops sudden, rapid decline in hemoglobin (≥0.5 g/dL per week or ≥4-5 g/L per week), transfusion requirement of ≥1 unit red cells per week, absolute reticulocyte count <10,000/μL (or <10 × 10⁹/L), and normal white cell and platelet counts 1, 2, 3

ESA-Induced PRCA Management

• The National Comprehensive Cancer Network recommends permanently discontinuing all ESA therapy, including epoetin alfa, darbepoetin alfa, and other erythropoietin products, if ESA-induced PRCA is suspected or confirmed 4, 5
• The National Comprehensive Cancer Network suggests not switching to alternative ESA products as neutralizing antibodies cross-react with all erythropoietin molecules 4, 5, 6

Anemia Management During Treatment

• The Kidney International journal recommends providing red blood cell transfusions as needed to maintain hemoglobin and prevent symptomatic anemia, and irradiating and filtering all blood products for aplastic anemia patients to prevent transfusion-associated complications 3, 7

Route of Administration Considerations

• The Kidney International Supplements journal notes that subcutaneous ESA administration carries significantly higher PRCA risk (0.5 cases per 10,000 patient-years), while intravenous ESA administration has not been associated with PRCA cases 1, 2

Common Pitfalls to Avoid

• The Journal of the National Comprehensive Cancer Network recommends never continuing ESA therapy after PRCA diagnosis, even at reduced doses, and avoiding switching between ESA products as this does not prevent cross-reactivity 4, 5, 6

Management of Pure Red Cell Aplasia

Alternative Management Strategies

• The National Comprehensive Cancer Network recommends immunosuppressive therapy, including corticosteroids, rituximab, cyclosporine, or cyclophosphamide, in select cases of PRCA, depending on the underlying etiology 8